The comparative study of metformin extended-release tablets in the treatment of metabolic disorder induced by antipsychotic

Objective: To study the efficacy and safety of metformin extended-release tablets on the metabolic disorder induced by antipsychotic.Methods: Seventy six schizophrenia patients with metabolic disorder induced by antipsychotic were divided into the treated group and control group randomly for 6 months.Monitor body mass index(BMI),fasting blood glucose(FBG) and blood lipid(TC,TG,LDL,HDL) at the end of 1,3 and 6 month.The Positive and Negative Symptom Scale(PANSS) and Treatment Emergent symptoms scale(TESS) were used to measure clinical efficacy.Results: It was decreased that BMI,TC,TG and LDL level at the end of 1 or 3 month in treated group,the differences were statistically significant(P<0.01),but there was no marked changes in the level of HDL and FBG(P>0.05).The differences of BMI,FBG,TG and HDL level were not significant in control group(P>0.05).At the end of 6 month,the differences of BMI,TC,TG,LDL and HDL level were statistically significant between the two groups(P<0.01).Before and after treatment,the scores of PANSS were not statistically significant between the two groups(P>0.05).Adverse reactions in the 2 groups were mild.Conclusions: It is effective and safe that metformin extended-release tablet treatment of metabolic disorder induced by antipsychotic,and does not affect the mental symptoms.